A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)-Reference-Cited by-同舟云学术

A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604)

Published:2015-03 Issue:3 Volume:67 Page:534-543
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Huddart Robert A.,Gabe Rhian,Cafferty Fay H.,Pollock Philip,White Jeff D.,Shamash Jonathan,Cullen Michael H.,Stenning Sally P.

Publisher

Elsevier BV

Subject

Urology

Reference32 articles.

1. International Germ Cell Cancer Collaborative, Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers;J Clin Oncol,1997

2. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy;Bower;Ann Oncol,1997

3. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.

4. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study;Nichols;J Clin Oncol,1998

5. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial;Chevreau;Eur Urol,1993

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases;Molecules;2022-04-11

2. Paclitaxel, Ifosfamide, and Cisplatin in Patients with Poor-prognosis Disseminated Nonseminomatous Germ Cell Tumors with Unfavorable Serum Tumor Marker Decline After First Cycle of Chemotherapy. The GCT-SK-003 Phase II Trial;European Urology Open Science;2021-11

3. Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery;European Urology Focus;2021-07

4. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium;Journal of Clinical Oncology;2021-05-10

5. Challenging presentations of germ cell tumours in routine clinical practice;Journal of the Royal College of Physicians of Edinburgh;2021-03